FDA 510(k) Premarket Notification

K173008 SCS 17-01

CLEARED

Dec 26, 2017
90 days to decision

K173008 · Product code: **MQV** · Orthopedic
Source: https://www.510kdatabase.net/k173008/

SUBMISSION DETAILS

Decision	Substantially Equivalent (Cleared)
Submission type	Traditional
Device classification	Filler, Bone Void, Calcium Compound (MQV)
Date received	Sep 27, 2017
Decision date	Dec 26, 2017
Days to decision	90 days
Third-party review	No
Summary / Statement	Summary

APPLICANT

Company	**Anika Therapeutics, Inc.**
Location	Beford, MA, US
Contact	Steven Chartier
Website	http://www.anikatherapeutics.com/
510(k) history	9 submissions · 9 cleared · 2017-2025

Anika Therapeutics, Inc. is a global leader in hyaluronic acid-based orthopedic regenerative solutions and osteoarthritis pain management. The company develops advanced tissue repair, cartilage regeneration, and injectable bone substitute technologies with a manufacturing facility in Bedford, US. Anika has received FDA 510(k) clearances from total submissions since 2017. Orthopedic devices represent the dominant focus of the company's regulatory portfolio. The latest clearance was received in 2025, reflecting active ongoing innovation and market engagement. The company's ...